Imiglucerase (Cerezyme)

Imiglucerase (Cerezyme) is covered only for the FDA‑approved indication of Type 1 Gaucher disease and excluded for all other indications. Approval (for 1 year) requires documented deficient β‑glucocerebrosidase activity or molecular genetic confirmation, prescribing by or consultation with an appropriate specialist (geneticist, endocrinologist, metabolic disorder or lysosomal storage disorder specialist), and dosing limited to 60 U/kg IV no more frequently than every 2 weeks.

"Cerezyme is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.